
    
      Phase I/II clinical trial to analyze safety and efficiency of intralesional application of
      the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic
      melanoma stage III/IV and unresectable metastasis. The antibody is directed against epitops
      of human CD28 and the melanoma associated surface antigen HMV-MAA. Treatment over 5 days with
      dose escalation.
    
  